17:14 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Constellation raises $60M in NASDAQ IPO

Epigenetics company Constellation Pharmaceuticals Inc. (NASDAQ:CNST) raised $60 million on July 18 through the sale of 4 million shares at $15 in a downsized IPO. Underwriters are J.P. Morgan, Jefferies, BMO Capital Markets and Oppenheimer....
00:51 , Jul 19, 2018 |  BC Extra  |  Financial News

Constellation slips after pricing $60M IPO

Constellation Pharmaceuticals Inc. (NASDAQ:CNST) dipped $3.52 (23%) to $11.48 Thursday after it raised $60 million through the sale of 4 million shares at $15 in a downsized IPO. Underwriters are J.P. Morgan, Jefferies, BMO Capital...
21:39 , Jun 23, 2018 |  BC Extra  |  Financial News

Latest batch of IPO filings: Rubius, Constellation, Replimune, Allakos

As a busy week for IPO pricings came to a close, several more companies filed for NASDAQ listings late Friday, further stocking an IPO pipeline of companies likely to seek liquidity during a tight calendar...
13:42 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Constellation raises $100M

Cancer epigenetics company Constellation Pharmaceuticals Inc. (Cambridge, Mass.) raised $100 million on April 9 in an untranched venture round from new investors Cormorant Asset Management, Deerfield Management, Fidelity Management, Hillhouse Capital, NS Investment, OrbiMed and...
10:59 , Apr 9, 2018 |  BC Extra  |  Financial News

Constellation raises $100M venture round

Cancer epigenetics company Constellation Pharmaceuticals Inc. (Cambridge, Mass.) raised $100 million in an untranched venture round from new investors Cormorant Asset Management, Deerfield Management, Fidelity Management, Hillhouse Capital, NS Investment, OrbiMed and Sirona Capital. Existing...
10:55 , Apr 9, 2018 |  BioCentury  |  Finance

Epigenetic experience

Constellation Pharmaceuticals Inc.’s scientific team and deep epigenetics pipeline enabled the company to garner an untranched $100 million venture round. New investors Cormorant Asset Management, Deerfield Management, Fidelity Management, Hillhouse Capital, NS Investment, OrbiMed Advisors...
02:35 , Dec 10, 2015 |  BC Extra  |  Financial News

Constellation raises $55M in mezzanine round

Epigenetics company Constellation Pharmaceuticals Inc. (Cambridge, Mass.) raised $55 million in a mezzanine round co-led by Topspin Partners and an undisclosed fund. Also participating were Third Rock Ventures, The Column Group, Venrock and SR One....
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Constellation, Genentech, Roche deal

Roche’s Genentech unit declined to exercise a one-time option to acquire Constellation. Genentech gained the option under a 2012 deal to discover and develop small molecules targeting multiple epigenetic target classes. Constellation said Genentech was...
01:53 , Aug 25, 2015 |  BC Extra  |  Company News

Constellation targets IPO after Genentech passes on takeout

Constellation Pharmaceuticals Inc. (Cambridge, Mass.) plans to tap the public markets now that the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) has declined to exercise a one-time option to acquire the epigenetics company. Genentech gained...
08:00 , Jan 5, 2015 |  BioCentury  |  Product Development

BETting early

Index Ventures-backed oncology play Oncoethix S.A. traded potentially larger returns for a faster clinical program for the company's primary asset when the Phase II program became too big for the small biotech to handle. On...